AstraZeneca drug does not extend lives of breast cancer patients – Financial Times

by
  1. AstraZeneca drug does not extend lives of breast cancer patientsFinancial Times
  2. AstraZeneca, competitor to Daiichi’s Trodelvy, fails to improve overall survival in breast cancer trialFierce biotechnology
  3. Datopotamab Deruxtecan Overall Survival Results Reported in Patients with Metastatic HR-Positive, HER2-Low or -Negative Breast Cancer in TROPION-Breast01 Phase 3 StudyBusiness news
  4. AstraZeneca shares fall on surprise miss for cancer drug that rivals GileadInvestors Business Daily
  5. AstraZeneca, Daiichi Sankyo’s ADC flops in Phase III breast cancer after misstep in lung cancerBiospace

Leave a Comment